This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
by Zacks Equity Research
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
by Zacks Equity Research
Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.
Viatris (VTRS) to Divest Some More Businesses, Shares Gain
by Zacks Equity Research
Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.
Novartis (NVS) Announces Positive Data on Kidney Disease Drug
by Zacks Equity Research
Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
by Zacks Equity Research
PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
by Zacks Equity Research
Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
by Zacks Equity Research
Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
by Zacks Equity Research
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
by Zacks Equity Research
Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) plunges on a surprise CRL by the FDA for its nasal spray curated for allergic reactions.
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Encompass Health (EHC) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Novartis' (NVS) Shareholders Approve Sandoz Separation
by Zacks Equity Research
Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
by Zacks Equity Research
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.
Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON)
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
by Zacks Equity Research
Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
by Zacks Equity Research
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
by Zacks Equity Research
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
by Zacks Equity Research
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Eton Pharmaceuticals, Inc. (ETON) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 300% and 84.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Meets Q4 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 0% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 28.57% and 15.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -100% and 19.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?